Scott Anderson

发表

Effect of PF-04217329 a prodrug of a selective prostaglandin EP(2) agonist on intraocular pressure in preclinical models of glaucoma.

P. Wells, C. Toris, Chau Almaden, 2011, Experimental eye research.

Ocular pharmacokinetics and hypotensive activity of PF-04475270, an EP4 prostaglandin agonist in preclinical models.

P. Wells, E. Rui, Chau Almaden, 2009, Experimental eye research.

In vivo evaluation of 11beta-hydroxysteroid dehydrogenase activity in the rabbit eye.

T. Quenzer, Hengmiao Cheng, H. Gukasyan, 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Correlation of in vitro and in vivo kinetics of nitric oxide donors in ocular tissues.

H. Gukasyan, S. Carreiro, A. Krauss, 2009, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

Pharmacokinetic-Pharmacodynamic and Response Sensitization Modeling of the Intraocular Pressure-Lowering Effect of the EP4 Agonist 5-{3-[(2S)-2-{(3R)-3-hydroxy-4-[3-(trifluoromethyl)phenyl]butyl}-5-oxopyrrolidin-1-yl]propyl}thiophene-2-carboxylate (PF-04475270)

P. Vicini, C. Xiang, K. Luu, 2009, Journal of Pharmacology and Experimental Therapeutics.

Carol F. Kirchhoff, Hugh D. Conlon, Scott Anderson, 2017, Biotechnology and bioengineering.

Retinal and Peripheral Nerve Toxicity Induced by the Administration of a Pan-Cyclin Dependent Kinase (cdk) Inhibitor in Mice

B. Jessen, M. Niesman, O. Illanes, 2006, Toxicologic pathology.